ArticleFrontiers in pharmacology2023

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma.

Nan Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.